ResMed Inc. (RMD) P/E Ratio History
Deep ValueTrading at 19.8x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 1997–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, ResMed Inc. (RMD) trades at a price-to-earnings ratio of 19.8x, with a stock price of $188.63 and trailing twelve-month earnings per share of $10.33.
The current P/E is 48% below its 5-year average of 38.0x. Over the past five years, RMD's P/E has ranged from a low of 21.7x to a high of 77.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, RMD is roughly in line with its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
The PEG ratio of 1.14 (P/E divided by 37% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, RMD trades roughly in line with the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RMD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RMD Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
RMD P/E vs Peers
Patient monitoring and respiratory care peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $25B | 25.0 | - | +224%Best | |
| $3B | 31.5 | 7.15 | -15% | |
| $1B | 8.7Lowest | - | +179% | |
| $102B | 22.0 | - | +31% | |
| $118B | 36.6 | 2.46Best | +8% | |
| $67B | 23.3 | - | +55% | |
| $17B | 24.8 | - | -20% | |
| $17B | 30.5 | - | -25% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
RMD Historical P/E Data (1997–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | - | $224.48 | $10.34 | 21.7x | -39% |
| FY2026 Q2 | Dec 31 2025 | $240.87 | $10.11 | 23.8x | -33% |
| FY2026 Q1 | - | $273.73 | $9.77 | 28.0x | -22% |
| FY2025 Q4 | Jun 30 2025 | $258.00 | $9.51 | 27.1x | -24% |
| FY2025 Q3 | Mar 31 2025 | $223.85 | $8.91 | 25.1x | -30% |
| FY2025 Q2 | - | $228.69 | $8.47 | 27.0x | -24% |
| FY2025 Q1 | Sep 30 2024 | $244.12 | $7.55 | 32.3x | -10% |
| FY2024 Q4 | Jun 30 2024 | $191.42 | $6.93 | 27.6x | -23% |
| FY2024 Q3 | Mar 31 2024 | $198.03 | $6.51 | 30.4x | -15% |
| FY2024 Q2 | Dec 31 2023 | $172.02 | $6.05 | 28.4x | -20% |
| FY2024 Q1 | Sep 30 2023 | $147.87 | $6.16 | 24.0x | -33% |
| FY2023 Q4 | Jun 30 2023 | $218.50 | $6.10 | 35.8x | +0% |
| FY2023 Q3 | Mar 31 2023 | $218.99 | $5.87 | 37.3x | +4% |
| FY2023 Q2 | Dec 31 2022 | $208.13 | $5.51 | 37.8x | +6% |
| FY2023 Q1 | Sep 30 2022 | $218.30 | $5.35 | 40.8x | +14% |
| FY2022 Q4 | - | $209.63 | $5.31 | 39.5x | +10% |
| FY2022 Q3 | - | $242.51 | $5.31 | 45.7x | +28% |
| FY2022 Q2 | Dec 31 2021 | $260.48 | $3.55 | 73.4x | +105% |
| FY2022 Q1 | - | $263.55 | $3.41 | 77.3x | +116% |
| FY2021 Q4 | Jun 30 2021 | $246.52 | $3.24 | 76.1x | +113% |
| FY2021 Q3 | Mar 31 2021 | $194.02 | $3.13 | 62.0x | +73% |
| FY2021 Q2 | - | $212.56 | $4.79 | 44.4x | +24% |
| FY2021 Q1 | Sep 30 2020 | $171.43 | $4.66 | 36.8x | +3% |
| FY2020 Q4 | - | $192.00 | $4.27 | 45.0x | +26% |
| FY2020 Q3 | - | $147.29 | $3.53 | 41.7x | +17% |
| FY2020 Q2 | - | $154.97 | $3.14 | 49.4x | +38% |
| FY2020 Q1 | Sep 30 2019 | $135.11 | $2.90 | 46.6x | +30% |
| FY2019 Q4 | Jun 30 2019 | $122.03 | $2.80 | 43.6x | +22% |
| FY2019 Q3 | Mar 31 2019 | $103.97 | $3.08 | 33.8x | -6% |
| FY2019 Q2 | Dec 31 2018 | $113.87 | $3.11 | 36.6x | +2% |
| FY2019 Q1 | Sep 30 2018 | $115.34 | $2.32 | 49.8x | +39% |
| FY2018 Q4 | Jun 30 2018 | $103.58 | $2.19 | 47.4x | +33% |
| FY2018 Q3 | Mar 31 2018 | $98.47 | $2.14 | 46.1x | +29% |
| FY2018 Q2 | Dec 31 2017 | $84.69 | $2.00 | 42.4x | +19% |
| FY2018 Q1 | Sep 30 2017 | $76.96 | $2.47 | 31.2x | -13% |
| FY2017 Q4 | Jun 30 2017 | $77.87 | $2.41 | 32.3x | -10% |
| FY2017 Q3 | Mar 31 2017 | $71.97 | $2.29 | 31.4x | -12% |
| FY2017 Q2 | Dec 31 2016 | $62.05 | $2.30 | 27.0x | -25% |
| FY2017 Q1 | Sep 30 2016 | $64.79 | $2.44 | 26.6x | -26% |
| FY2016 Q4 | - | $63.23 | $2.47 | 25.6x | -28% |
| FY2016 Q3 | - | $57.82 | $2.49 | 23.2x | -35% |
| FY2016 Q2 | - | $53.69 | $2.50 | 21.5x | -40% |
| FY2016 Q1 | Sep 30 2015 | $50.96 | $2.46 | 20.7x | -42% |
| FY2015 Q4 | - | $56.37 | $2.47 | 22.8x | -36% |
| FY2015 Q3 | - | $71.78 | $2.47 | 29.1x | -19% |
| FY2015 Q2 | Dec 31 2014 | $56.06 | $2.46 | 22.8x | -36% |
| FY2015 Q1 | - | $49.27 | $2.42 | 20.4x | -43% |
| FY2014 Q4 | Jun 30 2014 | $50.63 | $2.40 | 21.1x | -41% |
| FY2014 Q3 | Mar 31 2014 | $44.69 | $2.29 | 19.5x | -45% |
| FY2014 Q2 | - | $47.08 | $2.24 | 21.0x | -41% |
| FY2014 Q1 | Sep 30 2013 | $52.82 | $2.17 | 24.3x | -32% |
| FY2013 Q4 | Jun 30 2013 | $45.13 | $2.10 | 21.5x | -40% |
| FY2013 Q3 | Mar 31 2013 | $46.36 | $2.13 | 21.8x | -39% |
| FY2013 Q2 | Dec 31 2012 | $41.57 | $1.99 | 20.9x | -42% |
| FY2013 Q1 | Sep 30 2012 | $40.47 | $1.88 | 21.5x | -40% |
| FY2012 Q4 | Jun 30 2012 | $31.20 | $1.72 | 18.1x | -49% |
| FY2012 Q3 | Mar 31 2012 | $30.91 | $1.56 | 19.8x | -45% |
| FY2012 Q2 | Dec 31 2011 | $25.40 | $1.46 | 17.4x | -51% |
| FY2012 Q1 | Sep 30 2011 | $28.79 | $1.41 | 20.4x | -43% |
| FY2011 Q4 | - | $30.95 | $1.44 | 21.5x | -40% |
| FY2011 Q3 | - | $30.00 | $1.42 | 21.1x | -41% |
| FY2011 Q2 | Dec 31 2010 | $34.64 | $1.40 | 24.7x | -31% |
| FY2011 Q1 | - | $32.81 | $1.33 | 24.7x | -31% |
| FY2010 Q4 | Jun 30 2010 | $30.41 | $1.24 | 24.5x | -31% |
| FY2010 Q3 | Mar 31 2010 | $31.82 | $1.19 | 26.7x | -25% |
| FY2010 Q2 | - | $26.14 | $1.13 | 23.1x | -35% |
| FY2010 Q1 | Sep 30 2009 | $22.60 | $1.05 | 21.5x | -40% |
| FY2009 Q4 | - | $20.36 | $0.96 | 21.2x | -41% |
| FY2009 Q3 | - | $17.67 | $0.86 | 20.5x | -43% |
| FY2009 Q2 | Dec 31 2008 | $18.74 | $0.79 | 23.7x | -34% |
| FY2009 Q1 | - | $21.50 | $0.74 | 29.1x | -19% |
| FY2008 Q4 | Jun 30 2008 | $17.87 | $0.72 | 24.8x | -31% |
| FY2008 Q3 | Mar 31 2008 | $21.09 | $0.70 | 30.1x | -16% |
| FY2008 Q2 | Dec 31 2007 | $26.27 | $0.41 | 64.0x | +79% |
| FY2008 Q1 | Sep 30 2007 | $21.44 | $0.43 | 49.8x | +39% |
| FY2007 Q4 | Jun 30 2007 | $20.63 | $0.43 | 47.9x | +34% |
| FY2007 Q3 | Mar 31 2007 | $25.19 | $0.40 | 62.9x | +76% |
| FY2007 Q2 | Dec 31 2006 | $24.61 | $0.67 | 36.7x | +3% |
| FY2007 Q1 | Sep 30 2006 | $20.13 | $0.63 | 32.0x | -11% |
| FY2006 Q4 | Jun 30 2006 | $23.48 | $0.59 | 39.8x | +11% |
| FY2006 Q3 | Mar 31 2006 | $21.99 | $0.55 | 40.0x | +12% |
| FY2006 Q2 | Dec 31 2005 | $19.16 | $0.51 | 37.6x | +5% |
| FY2006 Q1 | Sep 30 2005 | $19.91 | $0.49 | 40.6x | +14% |
| FY2005 Q4 | - | $16.50 | $0.47 | 35.1x | -2% |
| FY2005 Q3 | - | $14.10 | $0.48 | 29.4x | -18% |
| FY2005 Q2 | Dec 31 2004 | $12.78 | $0.46 | 27.8x | -22% |
| FY2005 Q1 | - | $11.90 | $0.43 | 27.7x | -23% |
| FY2004 Q4 | Jun 30 2004 | $12.74 | $0.42 | 30.5x | -15% |
| FY2004 Q3 | Mar 31 2004 | $11.30 | $0.40 | 28.4x | -20% |
| FY2004 Q2 | Dec 31 2003 | $10.38 | $0.38 | 27.7x | -23% |
| FY2004 Q1 | - | $11.00 | $0.35 | 31.4x | -12% |
| FY2003 Q4 | Jun 30 2003 | $9.80 | $0.33 | 29.5x | -18% |
| FY2003 Q3 | Mar 31 2003 | $8.00 | $0.31 | 26.1x | -27% |
| FY2003 Q2 | - | $7.64 | $0.30 | 25.7x | -28% |
| FY2003 Q1 | Sep 30 2002 | $7.15 | $0.29 | 24.9x | -30% |
| FY2002 Q4 | Jun 30 2002 | $7.35 | $0.28 | 26.3x | -26% |
| FY2002 Q3 | Mar 31 2002 | $10.03 | $0.27 | 37.0x | +4% |
| FY2002 Q2 | Dec 31 2001 | $13.48 | $0.12 | 114.5x | +220% |
| FY2002 Q1 | Sep 30 2001 | $12.70 | $0.11 | 120.7x | +238% |
| FY2001 Q4 | Jun 30 2001 | $12.64 | $0.09 | 136.4x | +282% |
| FY2001 Q3 | Mar 31 2001 | $10.10 | $0.08 | 131.0x | +267% |
| FY2001 Q2 | Dec 31 2000 | $9.97 | $0.20 | 50.4x | +41% |
| FY2001 Q1 | Sep 30 2000 | $7.81 | $0.19 | 41.6x | +16% |
| FY2000 Q4 | Jun 30 2000 | $6.69 | $0.18 | 37.6x | +5% |
| FY2000 Q3 | Mar 31 2000 | $8.92 | $0.17 | 53.7x | +50% |
| FY2000 Q2 | Dec 31 1999 | $5.22 | $0.16 | 33.4x | -6% |
| FY2000 Q1 | - | $4.14 | $0.15 | 28.3x | -21% |
| FY1999 Q4 | Jun 30 1999 | $4.15 | $0.13 | 31.0x | -13% |
| FY1999 Q3 | Mar 31 1999 | $3.53 | $0.12 | 29.2x | -18% |
| FY1999 Q2 | - | $5.67 | $0.11 | 50.0x | +40% |
| FY1999 Q1 | Sep 30 1998 | $3.25 | $0.10 | 32.2x | -10% |
| FY1998 Q4 | - | $2.85 | $0.09 | 30.5x | -15% |
| FY1998 Q3 | - | $2.22 | $0.09 | 25.6x | -28% |
| FY1998 Q2 | Dec 31 1997 | $1.76 | $0.08 | 23.0x | -36% |
| FY1998 Q1 | - | $1.63 | $0.07 | 22.8x | -36% |
| FY1997 Q4 | Jun 30 1997 | $1.52 | $0.07 | 22.0x | -38% |
| FY1997 Q3 | Mar 31 1997 | $1.09 | $0.06 | 16.9x | -53% |
| FY1997 Q2 | - | $1.38 | $0.06 | 23.2x | -35% |
Average P/E for displayed period: 35.7x
Full Stock Analysis
Deep dive into RMD consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
29+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RMD — Frequently Asked Questions
Quick answers to the most common questions about buying RMD stock.
What is RMD's P/E ratio?
ResMed Inc. (RMD) trailing twelve-month P/E ratio is 19.8x, based on TTM diluted EPS of $10.33. The 5-year average P/E is 38.0x and the historical range spans 21.7x to 77.3x.
Is RMD stock overvalued or undervalued?
RMD trades at 19.8x P/E, below its 5-year average of 38.0x. At the 0th percentile of its historical range (21.7x–77.3x), the stock is priced at a discount to its own history.
Is RMD stock expensive?
No, RMD is not expensive on a historical basis. The current P/E of 19.8x is below the 5-year average of 38.0x and sits at the 0th percentile of its valuation range.
What is RMD's historical P/E range?
Over the past 5 years, RMD's P/E ratio has ranged from 21.7x to 77.3x, with a median of 32.3x and an average of 38.0x. The current P/E of 19.8x places the stock at the 0th percentile of this range. Full historical data spans 1997–2026.
How does RMD's P/E compare to the S&P 500?
RMD trades at 19.8x P/E versus the S&P 500 median of 24.4x. The 19% discount to the market suggests lower growth expectations or perceived higher risk.
How does RMD's valuation compare to Healthcare peers?
ResMed Inc. P/E of 19.8x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is RMD's PEG ratio?
RMD PEG ratio is 1.14, based on a P/E of 19.8x and EPS growth of 37.4%. A PEG between 1 and 2 suggests valuation aligns with growth expectations — typically considered fair.
What is RMD's earnings yield?
RMD earnings yield is 5.04%, the inverse of its 19.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.